IP International Journal of Orthopaedic Rheumatology
Official Publication of Indian Orthopaedic Rheumatology Association
Official Publication of Indian Orthopaedic Rheumatology Association
Print ISSN:-2581-8112
Online ISSN:-2581-9151
CODEN : IIJOAT
Original Article
Author Details :
Volume : 5, Issue : 2, Year : 2019
Article Page : 42-54
https://doi.org/10.18231/j.ijor.2019.010
Abstract
Spondyloarthropathy, a group of overlapping disorders of chronic inflammatory diseases of autoimmune nature has undergone critical changes in its management, specially with introduction of newer biologics and targeted synthetic DMARDs. Secukinumab and Tofacitinib are newer additions to proper management targeting various cytokines. Cost being an important factor in developing world, conventional synthetic DMARDs are being advocated to be used in situations where patient can not afford the treatment with biologics / small molecules i.e. JAK Inhibitors. It is heartening to know that methotrexate can achieve 20% remission in psoriatic arthritis almost equivalent to some biologics. Drug antibody is also a challenging problem in management with biologics.
Keywords: Biologic, DMARDs, Secukinumab, Tofacitinib, JAK Inhibitors, Cost.
How to cite : Jha S S, Spondyloarthropathy: A critical management analysis. IP Int J Orthop Rheumatol 2019;5(2):42-54
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution 4.0 International License, which allows others to remix, and build upon the work, the licensor cannot revoke these freedoms as long as you follow the license terms.
